SAGE Therapeutics Inc SAGE
$8.68 $0.02 (0.23%) 1D
Last Updated: Jul 30, 12:00 AM·BE
Pricing for DE stocks is delayed by 24 hours
Open navigation menu
Invest
Invest on your own
We do it for you
Halal tools
Screeners
Your portfolio
Calculators
Shariah
Our certifications
Learn
Education
Get help
Pricing
Company
About Musaffa
Investors
Build with us
Is SAGE Therapeutics Inc Stock Halal?
Shariah Compliance Analysis of SAGE Stock
Germany Health Care Small Cap No. As of September 2026, SAGE Therapeutics Inc (SAGE) is classified as NOT HALAL by Musaffa under its AAOIFI-based Shariah screening methodology. SAGE Therapeutics Inc does not pass Musaffa's business and financial screening criteria.
SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 353 full-time employees. The company went IPO on 2014-07-18. The firm has developed two FDA-approved treatments indicated for postpartum depression (PPD) and is advancing a portfolio of internally discovered novel chemical entities with the potential to become differentiated treatments designed to improve brain health by primarily targeting two critical central nervous system, receptor systems, GABA and NMDA. Its product ZURZUVAE is for the treatment of PPD in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, and is the first oral, once-daily, 14-day treatment specifically indicated for adults with PPD. The company is also evaluating potential indications for SAGE-324, a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing, including seizures in developmental and epileptic encephalopathies. Its other areas of focus are SAGE-319, SAGE-039, and SAGE-817.
SAGE Shariah Compliance
Screening Methodology: AAOIFI
As of September 2026, SAGE Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
SAGE Therapeutics Inc (SAGE) Chart
Financial Metrics & Statements of SAGE Therapeutics Inc (SAGE)
FAQ's for SAGE Therapeutics Inc (SAGE)
- As of September 2026, SAGE Therapeutics Inc SAGE is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes SAGE Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in SAGE Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of SAGE Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of SAGE Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of SAGE Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for SAGE Therapeutics Inc (SAGE)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
